PRZOOM - /newswire/ -
Franklin Lakes, NJ, United States, 2016/03/30 - BD has obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the BD BACTEC™ PEDS Plus™/F blood culture bottle in plastic, still available in glass - BD.com. NYSE: BDX
BD (Becton, Dickinson and Company), a leading global medical technology company, has obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the BD BACTEC™ PEDS Plus™/F blood culture bottle in plastic, still available in glass. This marks the fourth media culture bottle available in plastic across BD’s industry-leading BD BACTEC™ platform.
BD BACTEC™ PEDS Plus™/F Plastic Bottle
The new BD BACTEC™ PEDS Plus™/F plastic blood culture bottle is designed for customer convenience for the qualitative culture and recovery of aerobic microorganisms from pediatric and non-pediatric blood specimens less than 5 mL in volume. This latest addition to BD’s family of sepsis and healthcare associated infection solutions represents BD’s continued commitment to meeting customer needs and enhancing laboratory efficiencies. The BD plastic bottle offering is smaller and lighter, allowing for easier and safer handling during collection, transport and disposal.
“We are very pleased to announce the availability of the BD BACTEC PEDS Plus/F media in a plastic bottle,” said David Hickey, vice president and general manager of Microbiology Diagnostics Systems for BD Life Sciences Diagnostic Systems. “Sepsis, increasing at an annual rate of 8 percent to 13 percent1, continues to place tremendous public health and financial burden on our global health care communities. The availability of BD’s fourth media culture bottle in plastic demonstrates our ongoing commitment to delivering total solutions that are focused on optimizing clinical outcomes and laboratory efficiencies.”
The BD BACTEC blood culture platform (bd.com/ds), which includes the BD BACTEC™ blood culture instrument and resin media blood culture bottles, has been shown to improve bacterial recovery, facilitating changes in antibiotic treatment that facilitate antibiotic stewardship.2
BD (bd.com) is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and healthcare worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, optimize respiratory care and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has more than 45,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower healthcare delivery costs, increase efficiencies, improve healthcare safety and expand access to health.
Contact: Monique N. Dolecki - BD Investor Relations
P: 201-847-5378 - E: monique_dolecki[.]bd.com.
1. Global Sepsis Alliance Center for Sepsis Control & Care. The World Sepsis Declaration website. Accessed March 25, 2016.
2. Zadroga, R; Williams, DN: Hansen, GT “Selection of blood culture media matters- BACTEC use in the critically ill facilitates earlier organism detection and antibiotic decision making” WFSICCM Congress Durban 2013.